Azithromycin for Child Survival in Niger: Mortality and Resistance Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

864,493

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
MortalityResistance BacterialChild, Only
Interventions
DRUG

Azithromycin

"Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"

OTHER

Placebo

"Placebo will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"

Trial Locations (1)

Unknown

Programme national de santé oculaire, Niamey

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Ministry of Health, Niger

UNKNOWN

lead

University of California, San Francisco

OTHER

NCT04224987 - Azithromycin for Child Survival in Niger: Mortality and Resistance Trial | Biotech Hunter | Biotech Hunter